Results 71 to 80 of about 3,014 (182)

Kein Zusatznutzen aus formalen Gründen

Monitor Versorgungsforschung
„Fernab der Versorgungsrealität und ohne Berücksichtigung der Expertenmeinungen führender Fachgesellschaften”, lautet das Fazit von Johnson & Johnson zu dem Beschluss des Gemeinsamen Bundesausschusses (G-BA), der am 18.
Peter Stegmaier
doaj   +1 more source

Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real‐World Setting

Cancer Medicine
Background Somatic FGFR gene alterations (FGFRalt) may act as oncogenic drivers across several cancers. The prognostic impact of FGFRalt in solid tumors is not fully understood.
Levon Demirdjian, Spyros Triantos, Kristopher Standish, Shibu Thomas, Qi Xia, Jiarui Zhang, Joel Greshock, Julie Paone, Paige Sheridan, Shubham Pant, Christophe Massard, David A. Reardon, Yohann Loriot, Martin Schuler, Hussein Sweiti   +14 more
doaj   +1 more source

The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer [PDF]

Journal of Urologic Oncology
Dysregulation of fibroblast growth factor (FGF)-receptor (FGFR) signaling, which is implicated in various oncogenic processes, including tumor proliferation, survival, migration, invasion, and angiogenesis, has been identified as a critical factor in ...
Ho Kyung Seo, Eui Hyun Jung, Sora Yang, Hye Won Lee   +3 more
doaj   +1 more source

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib. [PDF]

, 2020
The treatment of metastatic melanoma has changed dramatically in the last decade with the introduction of immunotherapy and targeted therapy. A futile disease in the past is now treated with various options, resulting in improvement in progression-free ...
McIntosh, Alyson, MD, Sarkisian, Saro, Nair, Suresh G., MD, Callahan, Margaret, Shoushtari, Alexander N   +4 more
core   +1 more source

Patient tissue-derived FGFR4-variant and wild-type colorectal cancer organoid development and anticancer drug sensitivity testing

Heliyon
Objectives: FGFR4-variant and wild-type colorectal cancer (CRC) organoids were developed to investigate the effects of FGFR4-targeted drugs, including FGFR4-IN and erdafitinib, on CRC and their possible molecular mechanism.
Hailing Lin, Hongbo Fu, Shishen Sun, Hao Yin, Jie Yuan, Jilin Liao   +5 more
doaj   +1 more source

PATH-45. TREATMENT OF FGFR1 – ALTERED WHO GRADE 1 GLIONEURONAL TUMORS WITH FGFR INHIBITOR ERDAFITINIB

INTRODUCTION Low-grade mitogen-activated protein kinase (MAPK) pathway-altered glioneuronal tumors carry distinct molecular alterations, which may represent therapeutic opportunities to avoid or delay toxic treatments like radiation. Erdafitinib is a pan-
Gampel, Bradley, Gultekin, Sakir Humayun, Capo, Hilda, Williams, Basil, de la Fuente, Macarena I, Ivan, Michael E, Kushnirsky, Marina, Komotar, Ricardo J   +7 more
core   +1 more source

Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

, 2023
Overview of patients with urothelial cancer progressing on FGFR inhibitors, treatment outcomes, and postprogression sample availability. Granular view at the individual patient level.
Rastislav Bahleda (16617234), Giorgia Guaitoli (16827105), Francesco Facchinetti (16827090), David Combarel (16827111), Stefan Michiels (9081965), Antoine Hollebecque (15010338), Yoann Pradat (15352227), Santiago Ponce-Aix (16827114), Sergey I. Nikolaev (15061686), Luc Friboulet (15025943), Lambros Tselikas (15019536), Ludovic Bigot (16617254), Juan David Florez Arango (16827102), Hayato Mizuta (16827108), Benjamin Besse (15061674), Damien Vasseur (16827096), Cédric Pobel (16617263), Olivier Déas (16827099), Floriane Braye (16827093), Ken A. Olaussen (16827117), Yohann Loriot (15123021), Jean-Yves Scoazec (15036392)   +21 more
core   +1 more source

Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

, 2023
Synergistic effect of combinatorial treatments in patient-derived models of FGFR-driven urothelial cancer. A, In an MR86 PDX, combined erdafitinib–pictilisib (PI3K inhibitor) administration had synergistic effects leading to prolonged inhibition of tumor
Rastislav Bahleda (16617234), Giorgia Guaitoli (16827105), Francesco Facchinetti (16827090), David Combarel (16827111), Stefan Michiels (9081965), Antoine Hollebecque (15010338), Yoann Pradat (15352227), Santiago Ponce-Aix (16827114), Sergey I. Nikolaev (15061686), Luc Friboulet (15025943), Lambros Tselikas (15019536), Ludovic Bigot (16617254), Juan David Florez Arango (16827102), Hayato Mizuta (16827108), Benjamin Besse (15061674), Damien Vasseur (16827096), Cédric Pobel (16617263), Olivier Déas (16827099), Floriane Braye (16827093), Ken A. Olaussen (16827117), Yohann Loriot (15123021), Jean-Yves Scoazec (15036392)   +21 more
core   +1 more source

Erdafitinib Efficacious in Bladder Cancer [PDF]

Cancer Discovery, 2018
Abstract Findings from a phase II study indicate clinical efficacy with erdafitinib in patients with FGFR-altered inoperable or metastatic urothelial carcinoma. Robust responses were seen with this investigational pan-FGFR inhibitor, including in patients who did not respond to prior immunotherapy.
openaire   +1 more source

Skeletal overgrowth in a pre-pubescent child treated with pan-FGFR inhibitor

Heliyon
Fibroblast growth factors and their receptors (FGFR) have major roles in both human growth and oncogenesis. In adults, therapeutic FGFR inhibitors have been successful against tumors that carry somatic FGFR mutations.
Fataneh Majlessipour, Gaohui Zhu, Nicole Baca, Meenasri Kumbaji, Vivian Hwa, Moise Danielpour   +5 more
doaj   +1 more source